190 related articles for article (PubMed ID: 19153116)
1. Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.
Bidard FC; Tournigand C; André T; Mabro M; Figer A; Cervantes A; Lledo G; Bengrine-Lefevre L; Maindrault-Goebel F; Louvet C; de Gramont A
Ann Oncol; 2009 Jun; 20(6):1042-7. PubMed ID: 19153116
[TBL] [Abstract][Full Text] [Related]
2. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG).
Souglakos J; Androulakis N; Syrigos K; Polyzos A; Ziras N; Athanasiadis A; Kakolyris S; Tsousis S; Kouroussis Ch; Vamvakas L; Kalykaki A; Samonis G; Mavroudis D; Georgoulias V
Br J Cancer; 2006 Mar; 94(6):798-805. PubMed ID: 16508637
[TBL] [Abstract][Full Text] [Related]
3. Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure.
Kobayashi N; Shimamura T; Tokuhisa M; Goto A; Endo I; Ichikawa Y
Medicine (Baltimore); 2017 May; 96(19):e6769. PubMed ID: 28489753
[TBL] [Abstract][Full Text] [Related]
4. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741.
Sanoff HK; Sargent DJ; Campbell ME; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Goldberg RM
J Clin Oncol; 2008 Dec; 26(35):5721-7. PubMed ID: 19001325
[TBL] [Abstract][Full Text] [Related]
5. FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: a randomized phase III study (EAGLE Study).
Mishima H; Oba K; Sakamoto J; Muro K; Yoshino T; Hyodo I; Maehara Y
Jpn J Clin Oncol; 2012 Feb; 42(2):134-8. PubMed ID: 22167662
[TBL] [Abstract][Full Text] [Related]
6. Shifting to first-line regimen after previous failure of irinotecan and oxaliplatin containing chemotherapies in unresectable metastatic colorectal cancer: a retrospective study of case analysis.
Hsu CW; King TM; Lin CH; Wang HT; Ou WC; Wang JH
Int J Colorectal Dis; 2009 Apr; 24(4):377-83. PubMed ID: 19116722
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy for metastatic colon cancer: No effect on survival when the dose is reduced due to side effects.
Munker S; Gerken M; Fest P; Ott C; Schnoy E; Fichtner-Feigl S; Wiggermann P; Vogelhuber M; Herr W; Stroszczynski C; Schlitt HJ; Evert M; Reng M; Klinkhammer-Schalke M; Teufel A
BMC Cancer; 2018 Apr; 18(1):455. PubMed ID: 29685155
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases.
Miller CL; Taylor MS; Qadan M; Deshpande V; Worthington S; Smalley R; Collura C; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Parikh AR; Berger D; Tanabe KK; Lillemoe KD; Ferrone CR
J Gastrointest Surg; 2017 Nov; 21(11):1831-1840. PubMed ID: 28884391
[TBL] [Abstract][Full Text] [Related]
9. Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials.
Seligmann JF; Fisher D; Smith CG; Richman SD; Elliott F; Brown S; Adams R; Maughan T; Quirke P; Cheadle J; Seymour M; Middleton G
Ann Oncol; 2017 Mar; 28(3):562-568. PubMed ID: 27993800
[TBL] [Abstract][Full Text] [Related]
10. Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer.
Napolitano S; Woods M; Lee HM; De Falco V; Martini G; Della Corte CM; Martinelli E; Famiglietti V; Ciardiello D; Anderson A; Fowlkes NW; Villareal OE; Sorokin A; Kanikarla P; Coker O; Morris V; Altucci L; Tabernero J; Troiani T; Ciardiello F; Kopetz S
Clin Cancer Res; 2023 Jun; 29(12):2299-2309. PubMed ID: 37040395
[TBL] [Abstract][Full Text] [Related]
11. FOLFIRI-bevacizumab as a second-line treatment for advanced biliary tract cancer after gemcitabine-based chemotherapy.
Roussot N; Vincent J; Palmier R; Constantin G; Bengrine L; Fumet JD; Ghiringhelli F
Front Oncol; 2023; 13():1293670. PubMed ID: 38098503
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of irinotecan, 5-fluorouracil and leucovorin for treatment in patients with previously untreated advanced colorectal cancer.
Bae SB; Lee NS; Kim HJ; Kim KH; Kim HJ; Kim CK; Lee KT; Park SK; Won JH; Hong DS; Park HS
Cancer Res Treat; 2006 Apr; 38(2):72-7. PubMed ID: 19771263
[TBL] [Abstract][Full Text] [Related]
13. Soluble HLA-G expression levels and HLA-G/irinotecan association in metastatic colorectal cancer treated with irinotecan-based strategy.
Scarabel L; Garziera M; Fortuna S; Asaro F; Toffoli G; Geremia S
Sci Rep; 2020 May; 10(1):8773. PubMed ID: 32471996
[TBL] [Abstract][Full Text] [Related]
14. Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer.
Braun MS; Adab F; Bradley C; McAdam K; Thomas G; Wadd NJ; Rea D; Philips R; Twelves C; Bozzino J; MacMillan C; Saunders MP; Counsell R; Anderson H; McDonald A; Stewart J; Robinson A; Davies S; Richards FJ; Seymour MT
Br J Cancer; 2003 Oct; 89(7):1155-8. PubMed ID: 14520437
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study.
Choi IS; Choi M; Lee JH; Kim JH; Suh KJ; Lee JY; Kang B; Kim JW; Kim SH; Kim JW; Lee JO; Kim YJ; Bang SM; Lee JS; Lee KW
PLoS One; 2018; 13(6):e0198544. PubMed ID: 29879177
[TBL] [Abstract][Full Text] [Related]
16. A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: A nationwide health insurance database study.
Choi IS; Kim JH; Lee JH; Suh KJ; Lee JY; Kim JW; Kim SH; Kim JW; Lee JO; Kim YJ; Bang SM; Lee JS; Lee KW
PLoS One; 2018; 13(10):e0205853. PubMed ID: 30346970
[TBL] [Abstract][Full Text] [Related]
17. Retrospective analysis of the impact of dose delay and reduction on outcomes of colorectal cancer patients treated with FOLFIRI‑based treatment.
Zhang X; Zheng H; Cai C; Xu Y; Xie M; Wang Q; Jin X; Fu J
PeerJ; 2023; 11():e15995. PubMed ID: 37719110
[TBL] [Abstract][Full Text] [Related]
18. Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06).
Lim SH; Lee KW; Kim JJ; Im HS; Kim IH; Han HS; Koo DH; Cho JH; Maeng CH; Lee MY; Lee HJ; Kim JH; Park SG; Jung JY; Shin SH; Kim KH; Kim H; Oh SY; Kang M; Jung M; Rha SY
BMC Cancer; 2024 Feb; 24(1):252. PubMed ID: 38395832
[TBL] [Abstract][Full Text] [Related]
19. Managing life-threatening 5-fluorouracil cardiotoxicity.
Boldig K; Ganguly A; Kadakia M; Rohatgi A
BMJ Case Rep; 2022 Oct; 15(10):. PubMed ID: 36253013
[TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer - Results from a prospective cohort study.
Marschner N; Arnold D; Engel E; Hutzschenreuter U; Rauh J; Freier W; Hartmann H; Frank M; Jänicke M
Clin Epidemiol; 2015; 7():295-303. PubMed ID: 25945067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
